How to create a late-stage Biotech company in record time? Ask Novartis!

29/07/2015 - 3 minutes

Mereo BioPharma. This name doesn’t ring a bell? From now on, you should keep it in mind as it could rapidly become a rising star on the European Biotech scene. Launched five months ago, the company has already three candidates in phase II and just raised $119m (approximately €108m) from private investors! 

Mereo has everything needed to rapidly put a new drug on the market. The newborn company acquired a portfolio of three innovative clinical-stage development programmes from Novartis. In exchange, Novartis gains an equity stake in Mereo and milestones payement on future commercial successes.

Mereo’s initial mid-stage portfolio comprises three novel products. Each programme has a comprehensive dataset, including proof of concept clinical studies. Mereo’s pipeline comprises BPS-804, a monoclonal antibody to improve bone density (and thereby reduce fractures) in the orphan disease osteogenesis imperfecta, commonly known as brittle bone syndrome; BCT-197, an orally active p38 MAP kinase inhibitor being developed as first-line therapy against an acute pulmonary disease; and BGS-649 a novel orally active aromatase inhibitor aiming at normalizing the testosterone level in obese men with hypogonadotrophic hypogonadism.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member